Systematic Review: GLP-1 receptor agonists and SGLT-2 inhibitors are likely to reduce the risk of death from cardiovascular disease and death from any cause in people with both diabetes and established cardiovascular disease.

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis – Cochrane Library

Summary: The effects of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors for people with cardiovascular disease – Cochrane Library

Commentary on Twitter

The effects of DPP‐4 inhibitors, GLP‐1 receptor agonists and SGLT‐2 inhibitors for people with #CardiovascularDisease https://t.co/0FwffSCqbC New @CochraneHeart network meta-analysis looks at evidence from 31 studies. #CardiovascularResearch

— The Cochrane Library (@CochraneLibrary) October 27, 2021